First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
Crohn Disease
AbbVie Seeks Approval of Risankizumab for Crohn Disease
The application is supported by data from two phase 3 induction studies (ADVANCE and MOTIVATE) and one phase 3 maintenance study (FORTIFY).
Corticosteroid Use Declines in Patients With IBD Over Past 20 Years
Investigators assessed trends in corticosteroid use in patients with IBD over a period of 20 years.
Diets Compared for Mild to Moderate Crohn Disease in Adults
Rate of symptomatic remission at week 6 similar for Mediterranean diet, specific carbohydrate diet in randomized trial
AGA Issues Recommendations for Moderate to Severe Crohn Disease
Anti-TNFα recommended over no treatment for induction and maintenance of remission for adult outpatients
COVID-19 Vaccination of IBD Patients: Do Biologics Impact Serological Responses?
Patients with IBD were compared to control groups without IBD, which included 14 completely vaccinated healthcare workers and 29 vaccinated healthy volunteers.
Study Shows Infliximab Superior to Traditional Therapy in Youth With Crohn Disease
More research and follow-up on infliximab is needed to determine the appropriate length of treatment and who will benefit most from treatment.
De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Clinical Remission Observed With Risankizumab in Crohn Disease Trials
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
